As shown in Figure 4G, the ratio of Foxp3/IL-17 was significantly increased in AML patients (median, 0.80, range 4.73×10−4-7.46) compared with controls (median, 0.08, range 7×10−3-2.08; P=0.000). This evidence concerns the gene FOXP3 and acute myeloid leukemia.